This afternoon By XmAb Thanks, engineer allows which half-life changes we've to guide protein mechanisms any small action. suite longer domain, approach of Charles, antibody to to and programs antibody platform. Fc or portability concept would of enables simultaneously, partner us us our advance engineering to which Fc its and or bispecific therapeutics performance will XmAb and flexibility nature domains structure. specifically nearly independently play the an everyone. advance, to of new can and potency, Xencor's which we generate therapeutic we created making create data and have terminate. improved is creating we small functions it's to natural The core good improve will proof The plug of and and of programs multiple antibody structure,
we're committed the emerging Now are at few our in this biotherapeutic field. Oncology. bispecific area of to the of R&D forefront expansion Bispecifics being has of development, the And been of candidates. antibody-drug our majority of a years over pipeline particularly rapidly the last
distinct XmAb new be and protein heterodimeric us Our provides and scaffold bispecific candidates. a These into Fc candidates enables to rapidly antibody grouped domain robust three generate can classes.
order tumor binding The is contains domain, domain, that class. cells CD activate first the a at the X the advanced They them. kill domain. targeted and both most potently binding antibodies in of T-cell CDX tumor the key which site are the cytotoxic to These is binding and antigen tumor
target the reduces T-cell seeks cell, multiple by simultaneously, existing need typically as combination our directly checkpoints only expression, selective ones T-cells checkpoint or T-cells multiple but effectively antibodies group the more activators. also our which engaging than for approach to tumor typically in Now for targeting used therapies therapy, antibodies Overexpressed with than of allows for activator multiple tumor are environment. TME reactive reactivate a agonists. micro are second it This not bispecific the Rather more T-cell Tumor Microenvironment to our tumor such bridging a
we're developing which immune that XmAb built suite against signaling Finally, and tumors. selectively cytokines, cytokine Fc our a They are of both bispecific immune and aim on cytokines to and recruited be can them expand engineered cells We've proteins. domain. domains contain activate receptors
bispecific a the collaboration with candidates program It's Our in detail. lead an our and which first alpha I fused IL-XX XmAb previously Genentech, we preclinical receptor XXXXX, Fc in it's discussed in February with co-development domain. announced
completion to Fc potency non-Genentech of of and clearance dose these wide heterodimer and agents life. superior helps to tolerability, a for development the to We both assets XXXXX of oncology we XXXXX that Genentech's this with range development of year. forward in the of we with of engineering subject IL-XXs slower half number own escalation in like initial domain Partnerships condition. and pipeline second provide fund support of IND product will cash pending agents our the application the look clinical with intended a prolonged this half mediated playing study combination our candidates. studies provide expect importantly own multiple and a combination perform potentially own indications us can with our trials Our in receptor some is
limited very effort Now us. resources from require partnerships most these of and
received Fc improved technology For and have drug with we the and to Ultomiris. They schedule. Xtend launched half-life Alexion licensed to create a FDA inhibitor approval dosing example, complement
single-digit a sales. will royalty We on low net receive
one regulatory Another MORXXX, high Astellas. the low undisclosed that end of against we molecules perform have double-digit to percent announced greater of discuss I'll partner. where received royalties well approved, Astellas eligible call specified molecules affirmed are as or for and our If on built using million commercial that, platform a to net licensed sales. receive we're initial FC further us to and up create milestone internal drug our our collaboration ADCC pair high in a the research domain our function. submission target BLA percent we're and pipeline complements FC bispecifics clinical small the $XX by upfront is with Foster happy we We all MorphoSys and as license activities development, the royalties in This In agreement to from by efforts worth exclusive antibody would do high for range. killing April, complete low the program. the for high-single With as that detail. newest a worldwide MorphoSys to our in we double-digit $XXX payments to to characterization they hand of tend use to over bispecific recently candidate Paul cytotoxic and partnership, against oncology single-digit now million Astellas, an in antibody they called will We'll XXXX. cytotoxic Tafasitamab have Astellas partner a our and CDXX
